Brazil’s Ozempic Moment: Can Local Drugmakers Challenge Global Pharma Giants?
For years, Brazil has depended heavily on imported blockbuster medicines developed by multinational pharmaceutical companies. That may be about to change. Following the expiration of the Brazilian patent for semaglutide—the active ingredient in Novo Nordisk’s Ozempic—a race has begun among domestic pharmaceutical companies to produce more affordable alternatives. The development is about much more than […]
